Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience.
Innocenti I, Mosca A, Tomasso A, Galitzia A, Scarfò L, Morelli F, Galli E, Martini F, Sangiorgi E, Laureana R, Benintende G, Mattiello V, Chiriu S, Del Principe MI, Zamprogna G, Gentile M, Martino EA, Cappello E, Montalbano MC, Farina G, Innao V, Stirparo L, Patti C, Sportoletti P, Fresa A, Catania G, Coscia M, Bellesi S, Tedeschi A, Sanna A, Visentin A, Autore F, Pasquale R, Trentin L, Varettoni M, Ghia P, Murru R, Laurenti L. Innocenti I, et al. Among authors: laureana r. Hemasphere. 2024 Nov 28;8(12):e144. doi: 10.1002/hem3.144. eCollection 2024 Dec. Hemasphere. 2024. PMID: 39619246 Free PMC article. No abstract available.
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
Tissino E, Gaglio A, Nicolò A, Pozzo F, Bittolo T, Rossi FM, Bomben R, Nanni P, Cattarossi I, Zaina E, Zimbo AM, Ianna G, Capasso G, Forestieri G, Moia R, Datta M, Härzschel A, Olivieri J, D'Arena G, Laurenti L, Zaja F, Chiarenza A, Palumbo GA, Martino EA, Gentile M, Rossi D, Gaidano G, Del Poeta G, Laureana R, Del Principe MI, Maity PC, Jumaa H, Hartmann TN, Zucchetto A, Gattei V. Tissino E, et al. Among authors: laureana r. Leukemia. 2024 Oct;38(10):2127-2140. doi: 10.1038/s41375-024-02376-7. Epub 2024 Aug 14. Leukemia. 2024. PMID: 39143370 Free PMC article.
Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study.
Guarnera L, Tiravanti I, Guiducci A, Coppola L, Marinoni M, Nunzi A, Laureana R, Cardillo L, Esposito F, Secchi R, Buzzatti E, Paterno G, Pupo L, Sarmati L, Gattei V, Venditti A, Postorino M, Del Principe MI. Guarnera L, et al. Among authors: laureana r. Ann Hematol. 2024 Sep;103(9):3831-3833. doi: 10.1007/s00277-024-05815-8. Epub 2024 Jul 19. Ann Hematol. 2024. PMID: 39026027 No abstract available.
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.
Bomben R, Zucchetto A, Laureana R, Chiarenza A, Olivieri J, Tissino E, Rossi FM, Vit F, Bittolo T, Papotti R, Pozzo F, Gaglio A, Degan M, Polesel J, Marasca R, Visentin A, Moia R, Innocenti I, Vitale C, Murru R, Varettoni M, Tafuri A, Zaja F, Postorino M, Martino EA, Condoluci A, Rossi D, Cuneo A, Di Raimondo F, Sportoletti P, Del Giudice I, Foà R, Mauro FR, Coscia M, Laurenti L, Gaidano G, Trentin L, Principe MID, Gentile M, Gattei V. Bomben R, et al. Among authors: laureana r. Hemasphere. 2024 Jul 15;8(7):e128. doi: 10.1002/hem3.128. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39011128 Free PMC article. No abstract available.
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Pozzo F, Forestieri G, Vit F, Ianna G, Tissino E, Bittolo T, Papotti R, Gaglio A, Terzi di Bergamo L, Steffan A, Polesel J, Bulian P, Laureana R, Tafuri A, Chiarenza A, Di Raimondo F, Olivieri J, Zaja F, Laurenti L, Del Principe MI, Postorino M, Del Poeta G, Bomben R, Zucchetto A, Rossi D, Gattei V. Pozzo F, et al. Among authors: laureana r. Leukemia. 2024 Aug;38(8):1712-1721. doi: 10.1038/s41375-024-02301-y. Epub 2024 Jun 24. Leukemia. 2024. PMID: 38914716 Free PMC article.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Martino EA, Mauro FR, Reda G, Laurenti L, Visentin A, Frustaci A, Vigna E, Pepe S, Catania G, Loseto G, Murru R, Chiarenza A, Sportoletti P, Del Principe MI, Laureana R, Coscia M, Galimberti S, Ferretti E, Zucchetto A, Bomben R, Polesel J, Tedeschi A, Rossi D, Trentin L, Neri A, Morabito F, Gattei V, Gentile M. Martino EA, et al. Among authors: laureana r. Hematol Oncol. 2024 Jan;42(1):e3249. doi: 10.1002/hon.3249. Hematol Oncol. 2024. PMID: 38287529
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Moia R, Terzi di Bergamo L, Talotta D, Bomben R, Forestieri G, Spina V, Bruscaggin A, Cosentino C, Almasri M, Dondolin R, Bittolo T, Zucchetto A, Baldoni S, Del Giudice I, Mauro FR, Maffei R, Chiarenza A, Tafuri A, Laureana R, Del Principe MI, Zaja F, D'Arena G, Olivieri J, Rasi S, Mahmoud A, Al Essa W, Awikeh B, Kogila S, Bellia M, Mouhssine S, Sportoletti P, Marasca R, Scarfò L, Ghia P, Gattei V, Foà R, Rossi D, Gaidano G. Moia R, et al. Among authors: laureana r. Br J Haematol. 2023 Nov;203(3):416-425. doi: 10.1111/bjh.19052. Epub 2023 Aug 14. Br J Haematol. 2023. PMID: 37580908
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Morabito F, Tripepi G, Mauro FR, Laurenti L, Reda G, Moia R, Condoluci A, Vincelli I, Chiarenza A, Vigna E, Martino EA, Bruzzese A, Mezzatesta S, Laureana R, Cutrona G, Di Raimondo F, Fronza G, Zucchetto A, Bomben R, Rossi FM, Olivieri J, Zaja F, Rossi D, Gaidano G, Del Principe MI, Ilariucci F, Del Poeta G, Ferrarini M, Neri A, Gattei V, Gentile M. Morabito F, et al. Among authors: laureana r. Am J Hematol. 2023 Jul;98(7):E157-E160. doi: 10.1002/ajh.26927. Epub 2023 Apr 17. Am J Hematol. 2023. PMID: 37067157 Free article. No abstract available.
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Bomben R, Rossi FM, Vit F, Bittolo T, Zucchetto A, Papotti R, Tissino E, Pozzo F, Degan M, Polesel J, Bulian P, Marasca R, Reda G, Laurenti L, Olivieri J, Chiarenza A, Laureana R, Postorino M, Del Principe MI, Cuneo A, Gentile M, Morabito F, Fronza G, Tafuri A, Zaja F, Foà R, Di Raimondo F, Del Poeta G, Gattei V. Bomben R, et al. Among authors: laureana r. Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18. Leukemia. 2023. PMID: 36807650 Free PMC article. No abstract available.
COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
Del Poeta G, Laureana R, Bomben R, Rossi FM, Pozzo F, Zaina E, Cattarossi I, Varaschin P, Nanni P, Boschian Boschin R, Nunzi A, Postorino M, Pasqualone G, Brisotto G, Steffan A, Muraro E, Zucchetto A, Del Principe MI, Gattei V. Del Poeta G, et al. Among authors: laureana r. Hematol Oncol. 2023 Aug;41(3):559-562. doi: 10.1002/hon.3121. Epub 2023 Jan 9. Hematol Oncol. 2023. PMID: 36585917 Free PMC article. No abstract available.
14 results